One-year Results of the Effects of Rituximab on Acute Antibody-Mediated Rejection in Renal Transplantation

article

One-year Results of the Effects of Rituximab on Acute Antibody-Mediated Rejection in Renal Transplantation is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1097/TP.0000000000000958
P698PubMed publication ID26555944

P50authorMervilleQ3306691
Yvon LebranchuQ33292943
Bruno MoulinQ42713554
Marc HazzanQ67471891
Christophe LegendreQ89834063
Valérie ChâteletQ92568235
Bénédicte SautenetQ92692325
Philippe LangQ93102612
Didier DuclouxQ96350947
Benoit BarrouQ114429034
Claire Pouteil-NobleQ114452113
Emmanuel MorelonQ116996942
Olivier ToupanceQ116996945
Jean-Philippe RerolleQ116996946
Pierre François WesteelQ116996955
Raj PurgusQ116996959
Johnny SayeghQ116996975
P2093author name stringPhilippe Zaoui
Georges Mourad
Mathias Büchler
Amélie Le Gouge
Gilles Blancho
Caroline Freguin
Christine Mousson
Hedia Boivin
P433issue2
P407language of work or nameEnglishQ1860
P921main subjectantibodyQ79460
rituximabQ412323
P304page(s)391-399
P577publication date2016-02-01
P1433published inTransplantationQ15730500
P1476titleOne-year Results of the Effects of Rituximab on Acute Antibody-Mediated Rejection in Renal Transplantation: RITUX ERAH, a Multicenter Double-blind Randomized Placebo-controlled Trial
P478volume100

Reverse relations

cites work (P2860)
Q90198666A potential role of neutrophil extracellular traps (NETs) in kidney acute antibody mediated rejection
Q39130806A systematic review of the use of rituximab for the treatment of antibody-mediated renal transplant rejection.
Q60924756ABO-incompatible kidney transplantation as a renal replacement therapy-A single low-volume center experience in Japan
Q39105369Acute antibody-mediated rejection in kidney transplant recipients
Q38995172Anti-thymocyte globulins in kidney transplantation: focus on current indications and long-term immunological side effects.
Q39366396Antibody-mediated rejection across solid organ transplants: manifestations, mechanisms, and therapies
Q47773036Antibody-mediated rejection in young kidney transplant recipients: the dilemma of noncompliance and insufficient immunosuppression
Q52401610Antibody-mediated rejection: New approaches in prevention and management.
Q38812914Antithymocyte globulins in renal transplantation-from lymphocyte depletion to lymphocyte activation: The doubled-edged sword.
Q49680578Any Progress in the Treatment of Antibody-Mediated Rejection?
Q86421442B cell modulation in transplantation
Q56967420Banff survey on antibody-mediated rejection clinical practices in kidney transplantation: Diagnostic misinterpretation has potential therapeutic implications
Q39009557Chronic allograft injury: Mechanisms and potential treatment targets
Q90450246Circulating B Cells With Memory and Antibody-Secreting Phenotypes Are Detectable in Pediatric Kidney Transplant Recipients Before the Development of Antibody-Mediated Rejection
Q52586350Clinical Utility of Complement-Dependent C3d Assay in Kidney Recipients Presenting with Late Allograft Dysfunction.
Q55025247Clinical and histological evolution after de novo donor-specific anti-human leukocyte antigen antibodies: a single centre retrospective study.
Q93188012Comparing Plasmapheresis plus IVIg with Plasmapheresis plus IVIg plus Rituximab on the Management of Suspicious Antibody-Mediated Acute Rejection in Kidney Transplant Recipients
Q34841849Diagnosis and management of antibody-mediated rejection: current status and novel approaches
Q47286616Dynamic Prognostic Score to Predict Kidney Allograft Survival in Patients with Antibody-Mediated Rejection.
Q52336320Engineering therapeutic T cells to suppress alloimmune responses using TCRs, CARs, or BARs.
Q89746966Evaluation and Treatment of Acute Rejection in Kidney Allografts
Q92429175Extracorporeal photopheresis for the treatment of graft rejection in 33 adult kidney transplant recipients
Q64936489Follicular Helper T Cell Derived Exosomes Promote B Cell Proliferation and Differentiation in Antibody-Mediated Rejection after Renal Transplantation.
Q39708039Inflammation Causes Resistance to Anti-CD20-Mediated B Cell Depletion
Q48656799Lower tacrolimus exposure and time in therapeutic range increase the risk of de novo donor-specific antibodies in the first year of kidney transplantation
Q89367510Outcomes of Prolonged Treatment With Intravenous Immunoglobulin Infusions for Acute Antibody-mediated Rejection in Kidney Transplant Recipients
Q38668319Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients
Q90147875Prediction system for risk of allograft loss in patients receiving kidney transplants: international derivation and validation study
Q35659332Recent advances in renal transplantation: antibody-mediated rejection takes center stage
Q47157742Renal allograft rejection, lymphocyte infiltration, and de novo donor-specific antibodies in a novel model of non-adherence to immunosuppressive therapy
Q89905301Renal transplantation in 2016: Novel approaches to improve recipient and allograft outcomes
Q52656964Rituximab and Monitoring Strategies for Late Antibody-Mediated Rejection After Kidney Transplantation.
Q40461706Rituximab in Combination With Bortezomib, Plasmapheresis, and High-Dose IVIG to Treat Antibody-Mediated Renal Allograft Rejection.
Q37241071Rituximab in the treatment of refractory late acute antibody-mediated rejection: Our initial experience
Q41041729Rituximab use in late antibody-mediated rejection
Q47737016Targeting B Cells and Plasma Cells in Glomerular Diseases: Translational Perspectives.
Q42102593Treatment of Antibody-Mediated Rejection After Kidney Transplantation - 10 Years' Experience With Apheresis at a Single Center.
Q41967328Treatment of Antibody-Mediated Renal Allograft Rejection: Improving Step by Step
Q47920746Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: A multicenter, prospective, randomized, double-blind clinical trial.
Q58754949Treatment with plasmapheresis, immunoglobulins and rituximab for chronic-active antibody-mediated rejection in kidney transplantation: Clinical, immunological and pathological results
Q90344464Trough Level of Mycophenolic Acid Did Not Affect De Novo DSA Development in Kidney Transplantation
Q38769922Use of polyclonal/monoclonal antibody therapies in transplantation
Q34761349What's new in clinical solid organ transplantation by 2013.

Search more.